[1] OLSEN R W. GABAA receptor: Positive and negative allosteric modulators[J]. Neuropharmacology, 2018, 136: 10-22. doi:  10.1016/j.neuropharm.2018.01.036
[2] SIEGHART W, SAVIĆ M M. International union of basic and clinical pharmacology. CVI: GABAA receptor subtype- and function-selective ligands: key issues in translation to humans[J]. Pharmacol Rev, 2018, 70(4): 836-878. doi:  10.1124/pr.117.014449
[3] 侯成, 卢光照, 李文清, 等. 氟马西尼的药理、药效和剂型应用进展[J]. 药学实践杂志, 2017, 35(6): 485-489.
[4] TROTTI L M, ARNULF I. Idiopathic hypersomnia and other hypersomnia syndromes[J]. Neurotherapeutics, 2021, 18(1): 20-31. doi:  10.1007/s13311-020-00919-1
[5] RYE D B, BLIWISE D L, PARKER K, et al. Modulation of vigilance in the primary hypersomnias by endogenous enhancement of GABAA receptors[J]. Sci Transl Med, 2012, 4(161): 161ra151. doi:  10.3410/f.717969081.793468647
[6] TROTTI L M, SAINI P, KOOLA C, et al. Flumazenil for the treatment of refractory hypersomnolence: clinical experience with 153 patients[J]. J Clin Sleep Med, 2016, 12(10): 1389-1394. doi:  10.5664/jcsm.6196
[7] RONCARI G, TIMM U, ZELL M, et al. Flumazenil kinetics in the elderly[J]. Eur J Clin Pharmacol, 1993, 45(6): 585-587. doi:  10.1007/BF00315320
[8] SCHEEPERS L D, MONTGOMERY C J, KINAHAN A M, et al. Plasma concentration of flumazenil following intranasal administration in children[J]. Can J Anaesth, 2000, 47(2): 120-124. doi:  10.1007/BF03018846
[9] KELTY E, MARTYN V, O’NEIL G, et al. Use of subcutaneous flumazenil preparations for the treatment of idiopathic hypersomnia: a case report[J]. J Psychopharmacol, 2014, 28(7): 703-706. doi:  10.1177/0269881114523865
[10] 张鹰楠, 许子艺, 卢光照, 等. 喷雾剂临床应用及质量控制研究进展[J]. 药学实践与服务, 2024, 42(01): 1-5+17.
[11] 张鹰楠, 侯成, 许子艺, 等. 氟马西尼舌下片的制备及药动学研究[J]. 药学实践与服务, 2024, 42(3): 108-113. doi:  10.12206/j.issn.2097-2024.202305038
[12] 姜逸文. 氟马西尼用于全凭静脉麻醉术后催醒的临床研究[J]. 中国实用医药, 2017, 12(30): 161-162.
[13] 李冬梅, 李龙云, 焦宏伟, 等. 不同剂量咪达唑仑联合芬太尼在无痛支气管镜检查中的应用[J]. 中国实验诊断学, 2018, 22(10): 1797-1799.
[14] JANSSEN U, WALKER S, MAIER K, et al. Flumazenil disposition and elimination in cirrhosis. [J]. Clinical Pharmacology & Therapeutics, 1989 46.(3): 317-23.